Other languages Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
0.6354 ^USD	+0.86%		-2.08%	-26.77%

05-28	Unicycive Therapeutics, Inc. Delivers Multiple Presentations on Oxylanthanum Carbonate and Uni-494 At the European Renal Association Congress	CI
05-15	Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate At the National Kidney Foundation Spring Clinical Meeting	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Unicycive Therapeutics, Inc. Delivers Multiple Presentations on Oxylanthanum Carbonate and Uni-494 At the European Renal Association Congress	05-28
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate At the National Kidney Foundation Spring Clinical Meeting	05-15
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia	03-08
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	03-07
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate	23/10/23
Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors	06/09/23
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Unicycive Therapeutics Files Registration Statement on Behalf of Selling Stockholders	13/07/23
Top Midday Decliners	30/06/23
Unicycive Therapeutics' Shares Drop After US FDA Requested Additional Information on Lanthanum Dioxycarbonate Program	30/06/23
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed	30/06/23
Top Premarket Decliners	30/06/23
Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program	30/06/23
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
Unicycive Therapeutics to Raise up to $130 Million via Private Placement; Shares Soar	06/03/23
Unicycive Therapeutics Enters Into License Accord With Lotus Pharmaceutical for Renazorb in South Korea	02/02/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Other languages

Filters